TNF and inflammatory bowel disease: However, in contrast to studies providing evidence of the safety of anti-TNF-α preparations during pregnancy, a review of more than 120,000 adverse events voluntarily reported to the FDA after drug exposure revealed 61 congenital abnormalities in 41 children of 40 mothers exposed to TNF-α blockers for various indications, including IBD [56].